Iconovo AB (OSTO:ICO) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ICO Iconovo AB OSTO:ICO
34 GF Score
Price kr1.08
GF Value kr0.27
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Iconovo AB Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

OSTO:ICO
34GF Score
Iconovo AB OSTO:ICO
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Iconovo AB (OSTO:ICO) Overvalued in 2026?

Based on GuruFocus' analysis, Iconovo AB stock appears to be overvalued. The current stock price of kr1.08 is trading 300% above its estimated GF Value™ of kr0.27. GuruFocus considers Iconovo AB to be Significantly Overvalued.

Key valuation signals for OSTO:ICO:

  • Dividends Received:
  • GF Value™: kr0.27 vs. price of kr1.08 (300% above fair value)
  • GF Score™: 34/100 with 5 warning signs

No single metric tells the full story. See the OSTO:ICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Iconovo AB Business Description

Address Ideongatan 3 A-B, Delta 6, Lund, SWE, SE-223 62
Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.
34GF Score

Get the complete analysis for OSTO:ICO

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.08
Price
kr0.27
GF Value